A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVB Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)